Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Clinical Study of Safety and Tolerability of Oral Xeloda (Capecitabine) in Adjuvant Treatment of Resected Cancer of the Colon

NCT02581423 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02581423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02581423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Clinical Study of Safety and Tolerability of Oral Xeloda (Capecitabine) in Adjuvant Treatment of Resected Cancer of the Colon
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2005
Completion date
March 31, 2007
Enrollment
63 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer